SYRS News and Press, Syros Pharmaceuticals Inc. From 08/07/23

2023-08-07 12:46:32 ET Syros Pharmaceuticals ( NASDAQ: SYRS ) is scheduled to announce Q2 earnings results on Tuesday, August 8th, before market open. The consensus EPS Estimate is -$1.13 and the consensus Revenue Estimate is $3.5M (-44.3% Y/Y). Over the last 2 years, ...

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Tuesday, August 8, 2023 to report its seco...

2023-07-21 17:17:13 ET Gainers: Gritstone bio ( GRTS ) +4.8% . LexinFintech Holdings ( LX ) +4.3% . AppLovin ( APP ) +2.9% . Latham Group ( SWIM ) +2.6% . Accuray ( ARAY ) +2.5% . Losers: ALX Oncology Holdings ( ALXO ...

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will present a corporate overview at the Sidoti June 2023 ...

-- New data support further evaluation of SY-5609 for PDAC and HR+ breast cancer and demonstrate significant potential for SY-5609 in a wide range of tumor types and combinations -- -- Consistent with prior guidance, exploring partnership opportunities to advance development...

2023-05-10 22:12:05 ET Syros Pharmaceuticals, Inc. (SYRS) Q1 2023 Earnings Conference Call May 10, 2023, 08:30 ET Company Participants Karen Hunady - Director, Investor Relations and Corporate Communications Nancy Simonian - President, CEO & Director David Ro...

2023-05-10 07:32:55 ET Syros Pharmaceuticals press release ( NASDAQ: SYRS ): Q1 GAAP EPS of -$0.85 beats by $0.20 . Revenue of $3M (-45.2% Y/Y) misses by $0.3M . Cash, cash equivalents and marketable securities as of March 31, 2023 were $166 million, as compa...

-- On track to complete enrollment of 190 patients in 4Q 2023, with pivotal complete response (CR) data from SELECT-MDS-1 expected in 3Q 2024 -- -- Amended SELECT-MDS-1 study to add overall survival as key secondary endpoint -- -- Initial data from the randomized portion o...

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a fireside chat at the JMP Securities ...

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Wednesday, May 10, 2023 to report its firs...